Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age

Blood

Volumn 95, Issue 4, 2000, Pages 1188-1194

  Deeg, H Joachim ^a,b   Shulman, H M ^a   Anderson, J E ^a   Bryant, E M ^a   Gooley, T A ^a   Slattery, J T ^a   Anasetti, C ^a   Fefer, A ^a   Storb, R ^a   Appelbaum, F R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLAST TRANSFORMATION; CAUSE OF DEATH; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOGRAFT; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RELAPSE; SURGICAL RISK; SURVIVAL; TREATMENT OUTCOME;

EID: 0034651960     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.4.1188.004k38_1188_1194     Document Type: Article

References (47)

1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079.
2. Noel P, Solberg LA Jr. Myelodysplastic syndromes: pathogenesis, diagnosis and treatment. Crit Rev Oncol Hematol. 1992;12:193.
3. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992;82:358.
4. Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood. 1996;88:358.
5. Cahn JY, Labopin M, Schattenberg A, et al. Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years: acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia. 1997;11:416.
6. Zikos P, Van Lint MT, Frassoni F, et al. Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate. Blood. 1998;91:3503.
7. Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 1993;82:677.
8. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors Blood. 1996;87:51.
9. Appelbaum FR, Storb R, Ramberg RE, et al. Treatment of preleukemic syndromes with marrow transplantation. Blood. 1987;69:92.
10. DeWitte T, Zwaan F, Hermans J, et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol. 1990;74:151.
11. Ramsay NKC, Kersey JH, Robison LL, et al. A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med. 1982; 306:392.
12. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98:461.
13. Du W, Dansey R, Abella EM, et al. Successful allogeneic bone marrow transplantation in selected patients over 50 years of age - a single institution's experience. Bone Marrow Transplant. 1998;21:1043.
14. Miller CB, Piantadosi S, Vogelsang GB, et al. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol. 1996;14:1327.
15. Copelan EA, Kapoor N, Berliner M, Tutschka PJ. Bone marrow transplantation without total-body irradiation in patients aged 40 and older. Transplantation. 1989;48:65.
16. Klingemann H-G, Storb R, Fefer A, et al. Bone marrow transplantation in patients aged 45 years and older. Blood. 1936;67:770.
17. Anderson JE, Anasetti C, Appelbaum FR, et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol. 1996;93:59.
18. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:626.
19. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. BrJ Haematol. 1976;33:451.
20. Morel P, Hebbar M, Lai J-L, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia. 1993;7:1315.
21. Nevill TJ, Fung HC, Shepherd JD, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood. 1998;92:1910.
22. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 1995;86:3542.
23. Hamblin T. The treatment of acute myeloid leukaemia preceded by the myelodysplastic syndrome. Leuk Res. 1992;16:101.
24. Anderson JE, Appelbaum FR, Deeg HJ, Storb R. Phase II study of busulfan (busulfan) and total body irradiation (TBI) as a novel preparative regimen in allogenic marrow transplantation (BMT) for advanced myelodysplastic syndrome [abstract]. Leuk Res. 1999;23.
25. Anderson JE, Appelbaum FR, Barnett T, Chauncey TR, Flowers M, Storb R. Relapse after allogeneic bone marrow transplantation (BMT) for myelodysplasia (MDS) subtype refractory anemia (RA) is increased by shielding lungs and liver during irradiation [abstract]. Blood. 1998;92(suppl 1):659a.
26. O'Donnell MR, Long GD, Parker PM, et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol. 1995;13:2973.
27. Nevill TJ, Shepherd JD, Reece DE, et al. Treatment of myelodysplastic syndrome with busulfancyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant. 1992;10: 445.
28. Ratanatharathorn V, Karanes C, Uberti J, et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood. 1993;81:2194.
29. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89:3055.
30. Demirer T, Buckner CD, Appelbaum FR, et al. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant. 1996;17:341.
31. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit. 1998;20:543.
32. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92:3515.
33. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729.
34. Deeg HJ, Lin D, Leisenring W, et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood. 1997;89:3880.
35. Deeg HJ, Yamaguchi M. Acute graft-versus-host disease. In: Atkinson K, ed. Clinical Bone Marrow and Blood Stem Cell Transplantation: A Reference Book. Cambridge, United Kingdom: Cambridge University Press [in press].
36. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988; 6:1562.
37. Durnam DM, Anders KR, Fisher L, O'Quigley JO. Bryant EM, Thomas ED. Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay. Blood. 1989;74:2220.
38. Scharf SJ, Smith AG, Hansen JA, McFarland C, Erlich HA. Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood. 1995;85:1954.
39. Sievers EL, Lange BJ, Buckley JD, et al. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. J Natl Cancer Inst. 1996;88:1483.
40. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063.
41. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457.
42. Pepe MS, Longton G, Pettinger M, Mori M, Fisher LD, Storb R. Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: motivation for and description of new methods. Br J Haematol 1993; 83:602.
43. Slattery JT, Sanders JE, Buckner CD. et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31.
44. Anderson JE, Appelbaum FR. Myelodysplasia and myeloproliferative disorders. Curr Opin Hematol. 1997;4:261.
45. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962.
46. Rapoport AP, DiPersio JF, Martin BA, et al. Patients > or = age 40 years undergoing autologous or allogeneic BMT have regimen-related mortality rates and event-free survivals comparable to patients < age 40 years. Bone Marrow Transplant. 1995;15:523.
47. Drobyski WR, Pelz C, Kabler-Babbitt C, Hessner M, Baxter-Lowe LA, Keever-Taylor CA. Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia. Biol Blood Marrow Transplant. 1998;4:3.